SPECIFIC-INHIBITION OF THE ACTIVITY OF THE UROKINASE RECEPTOR-MEDIATED CELL-SURFACE PLASMINOGEN ACTIVATION SYSTEM BY SURAMIN

被引:19
作者
ELLIS, V
DANO, K
机构
[1] Finsen Laboratory, Rigshospitalet, Copenhagen, DK-2100
关键词
D O I
10.1042/bj2960505
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urokinase-type plasminogen activator (uPA) is involved in generating the proteolytic activity necessary for invasive processes, and is dependent on binding to its specific cellular receptor (uPAR) for efficient function. We report here that the polysulphonated napthylurea compound suramin inhibits the activity of this cell-associated proteolytic system, in a manner independent of its antagonism of the uPA-uPAR interaction [Behrendt, Ronne and Dano (1993) J. Biol. Chem. 268, 5985-5989], occurring at a 25-100-fold-lower suramin concentration. This inhibition was found to be due to effects on the activation of both pro-uPA and plasminogen. Suramin inhibited plasmin activation of pro-uPA by a non-competitive mechanism (K(i) approx. 2 mug/ml), which did not involve a direct effect on plasmin catalytic activity. Similarly, its effect on plasminogen activation was not due to a direct inhibition of uPA. The inhibition of plasminogen activation, which occurred exclusively with receptor-bound uPA, appeared to be due to a reversal of the favourable kinetics which result from the activation of cell-associated plasminogen, although suramin did not inhibit the cellular binding of I-125-labelled plasminogen. This suggests that this effect is due to interference with interactions between components of this system on the cell surface, and that suramin may be useful in gaining further insight into the molecular mechanisms involved in the functional assembly of this proteolytic system. Furthermore the effective inhibition of this system by suramin indicates an anti-invasive potential that may contribute to the anti-tumour effect of suramin in vivo.
引用
收藏
页码:505 / 510
页数:6
相关论文
共 34 条
[1]  
APPELLA E, 1987, J BIOL CHEM, V262, P4437
[2]  
BEHRENDT N, 1993, J BIOL CHEM, V268, P5985
[3]   EFFICIENT REVERSION OF SIMIAN SARCOMA VIRUS-TRANSFORMATION AND INHIBITION OF GROWTH FACTOR-INDUCED MITOGENESIS BY SURAMIN [J].
BETSHOLTZ, C ;
JOHNSSON, A ;
HELDIN, CH ;
WESTERMARK, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (17) :6440-6444
[4]  
BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0
[5]   SURAMIN INHIBITION OF GROWTH-FACTOR RECEPTOR-BINDING AND MITOGENICITY IN AKR-2B CELLS [J].
COFFEY, RJ ;
LEOF, EB ;
SHIPLEY, GD ;
MOSES, HL .
JOURNAL OF CELLULAR PHYSIOLOGY, 1987, 132 (01) :143-148
[6]   EXPERIMENTAL ANIMAL-MODEL FOR MUCOPOLYSACCHARIDOSIS - SURAMIN-INDUCED GLYCOSAMINOGLYCAN AND SPHINGOLIPID ACCUMULATION IN THE RAT [J].
CONSTANTOPOULOS, G ;
REES, S ;
CRAGG, BG ;
BARRANGER, JA ;
BRADY, RO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (06) :3700-3704
[7]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[8]   THE DETERMINATION OF ENZYME INHIBITOR CONSTANTS [J].
DIXON, M .
BIOCHEMICAL JOURNAL, 1953, 55 (01) :170-171
[9]  
EISEN V, 1973, BRIT J PHARMACOL, V49, P678, DOI 10.1111/j.1476-5381.1973.tb08544.x
[10]  
ELLIS V, 1991, J BIOL CHEM, V266, P12752